Rizza W, Veronese N, Fontana L
Pre-treatment considerations should include: Disease activity assessment : GLP-1 agonists should ideally be initiated when Crohn's disease is in remission or well-controlled, as distinguishing medication side effects from disease flare becomes challenging during active inflammation Nutritional status evaluation : Patients with Crohn's disease may already have compromised nutritional status
Each patient has distinct needs and wellness goals, so the price of this treatment can vary
De Laet C, Kanis J, Odn A, Johanson H, Johnell O, Delmas P, et al
Convenience: There is no need to visit a healthcare provider for injections
Finerenones kidney-protective effects likely stem from suppression of inflammatory and pro-fibrotic pathways [73]